NEW YORK (GenomeWeb News) – Rodney Markin has joined Trovagene's board of directors, and Chris McGuigan has resigned from the company's board to focus on other opportunities, Trovagene said this week.

Markin is chairman of Transgenomic, chief technology officer and associate vice chancellor for business development at the University of Nebraska Medical Center, and a professor of pathology and microbiology and surgery at the university.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.